Asenapine Tablet
Product Images NDC 46708-198

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Asenapine (NDC 46708-198). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Asenapine-10mg.jpg (Asenapine 10mg)

Not available.*

FDA Label Image

Asenapine 25mg

FDA Label Image

Asenapine-5mg.jpg (Asenapine 5mg)

The text is not-readable.*

FDA Label Image

Asenapine Figure1

This text provides information on the potential changes in pharmacokinetic parameters such as Cmax and AUC when certain drugs are co-administered with inhibitors of specific cytochrome P450 enzymes. The drugs mentioned include fluvoxamine, imipramine, paroxetine, carbamazepine, and valproate, among others. The text also reports a specific example of how fluvoxamine can affect the exposure of asenapine.*

FDA Label Image

Asenapine Figure2

This text provides information about the effect of certain drugs on the metabolism of other drugs by different enzymes. It includes data on the change in peak plasma concentration (Cmax) and area under the curve (AUC) for substrate/inhibitor drugs of CYP1A2/2C19/3A4 and CYP2C19/2D6 enzymes. There is also information on the inhibitory effect of Paroxetine on its own metabolism and the weak inhibitory effect of Asenapine on CYP206, based on studies with healthy subjects. Additionally, it is reported that coadministration of Asenapine and Imipramine did not affect the plasma concentrations of the metabolite Desipramine.*

FDA Label Image

Asenapine Figure3

This figure presents the effect of intrinsic factors on the pharmacokinetics of Asenapine. It shows the population description, including renal and hepatic impairment, smoking status, and ethnicity. The figure provides information on Cmax and AUC, as well as fold change and 90% CI. The data for renal and hepatic impairment are relative to subjects with normal function, and the data for smokers are relative to non-smokers. The Japanese data is relative to Caucasians.*

FDA Label Image

Asenapine Figuree

FDA Label Image

Figure A (Asenapine Figurea)

The text "Tablet Pack" suggests that there might be a packaging designed specifically for tablets - this could refer to either electronic tablets or tablet medication. The mention of the "Thumb Button" is too vague to provide any useful context about what the button is for.*

FDA Label Image

Step 2 (Asenapine Figureb)

FDA Label Image

Step 3 (Asenapine Figurec)

FDA Label Image

Asenapine Figured

FDA Label Image

Figure F (Asenapine Figuref)

FDA Label Image

Structure (Asenapine Structure)

FDA Label Image

Asenapine Tabletpack

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.